Previous 10 | Next 10 |
CHESTERBROOK, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President &am...
Trevena, Inc. (TRVN) Q1 2022 Earnings Conference Call May 11, 2022 08:00 AM ET Company Participants Barry Shin - Senior Vice President & Chief Financial Officer Carrie Bourdow - President & Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack - Chief Medical O...
Trevena (NASDAQ:TRVN) stock fell ~30% on May 11 after the company reported its Q1 results. Net loss widened to -$16.39M, compared to -$9.84M in Q1 2021 Total revenue declined to $20K, compared to $209K in the year ago period. Trevena had License revenue of $20K and no product revenue in ...
Trevena press release (NASDAQ:TRVN): Q1 GAAP EPS of -$0.10. Revenue of $0.02M (-90.5% Y/Y). Cash and cash equivalents were $48.7M as of March 31, 2022, which the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into 2023....
OLINVYK refocused commercial strategy initiated mid-Q1 OLINVYK respiratory physiology study demonstrated statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects Cognitive function study for OLINVYK versu...
Trevena (NASDAQ:TRVN) is scheduled to announce Q1 earnings results on Wednesday, May 11th, before market open. The consensus EPS Estimate is -$0.09 (-50.0% Y/Y) and the consensus Revenue Estimate is $0.35M (+66.7% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 ...
OTCQX:ADRNY, AGFY, BKSY, BLRX, DNUT, OTCPK:EONGY, EVGO, EXK, FLNG, FREY, FVRR, GMAB, ICL, INVZ, KRNT, LIVE, MCFT, OTCPK:NLLSF, NOMD, ONDS, PDSB, PFGC, PIRS, PRGO, PSFE, OTCPK:SPNX, TAK, TM, TRVN, WEN, WWR, WWW, XERS, YETI, ZOM For Seeking Alpha's full earnings season calendar, click here...
CHESTERBROOK, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial...
Wuhan Binhui Biopharm closed a $47 million Series B financing to support its R&D of oncolytic virus products. Amoy Diagnostics, a Shanghai novel molecular diagnostics company, signed a collaboration agreement to develop companion diagnostics for AstraZeneca drugs. Hangzhou Asc...
Trevena (NASDAQ:TRVN) reported data from a study evaluating opioid drug Olinvyk (oliceridine) injection versus morphine for managing acute pain in elderly/overweight. The company said the study builds on the collaborative work with Albert Dahan and his research team at Leiden Univer...
News, Short Squeeze, Breakout and More Instantly...
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing ...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...